Sanofi (SAN.PA)
| Previous close | 87.70 |
| Open | 87.68 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 87.63 - 88.37 |
| 52-week range | 80.60 - 104.90 |
| Volume | |
| Avg. volume | 1,365,420 |
| Market cap | 111.739B |
| Beta (5Y monthly) | 0.45 |
| PE ratio (TTM) | 20.55 |
| EPS (TTM) | 4.30 |
| Earnings date | 25 Apr 2024 |
| Forward dividend & yield | 3.76 (4.29%) |
| Ex-dividend date | 13 May 2024 |
| 1y target est | 105.70 |
- Reuters
UPDATE 2-Sanofi profit slips on generic competition and currency effects
Sanofi's first-quarter operating income fell 14.7% as currency effects and cheap competition to its multiple sclerosis drug Aubagio outweighed rising sales of anti-inflammatory drug Dupixent, the French drugmaker said on Thursday. Operating income adjusted for one-offs slipped to 2.84 billion euros ($3.04 billion), a touch above the 2.79 billion euros expected by analysts in a poll on Sanofi's website. The company reiterated that it expects 2024 adjusted earnings per share (EPS) to slip by a low single-digit percentage, excluding currency swings, citing higher taxes and an increase in development expenditure.
ReutersSanofi profit slips on generic competition and currency effects
(Reuters) -Sanofi's first-quarter operating income fell 14.7% as currency effects and cheap competition to its multiple sclerosis drug Aubagio outweighed rising sales of anti-inflammatory drug Dupixent, the French drugmaker said on Thursday. Operating income adjusted for one-offs slipped to 2.84 billion euros ($3.04 billion), a touch above the 2.79 billion euros expected by analysts in a poll on Sanofi's website. The company reiterated that it expects 2024 adjusted earnings per share (EPS) to slip by a low single-digit percentage, excluding currency swings, citing higher taxes and an increase in development expenditure.
GlobeNewswirePress Release: Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance
Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance Paris, April 25, 2024 Sales growth of 6.7% at CER and business EPS(1) of €1.78 Dupixent sales up 24.9% to €2,835 million, on target to deliver ~€13bn in 2024Pharma launches up 90.5% to €606 million, led by Nexviazyme and ALTUVIIIOVaccines sales up 5.6%, boosted by BeyfortusConsumer Healthcare (CHC) up 9.0%, benefiting from the Qunol acquisition in Physical and Mental Wellness and strong Digestive Wellness performa
